JOPIC
Journal of Pulmonology and Intensive Care

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine.

eISSN: 2980-0803
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Ischemia-modified albumin as a marker of disease severity and hospitalization in community-acquired pneumonia: a prospective case–control study
Abstract
Aims: Community-acquired pneumonia (CAP) is an important public health problem because of its high morbidity, mortality, and health care costs. Many biomarkers have been used to determine the severity and prognosis of pneumonia. Ischemia-modified albumin (IMA) is a marker of the recently used oxidant-antioxidant mechanism and has been found to increase in many inflammatory conditions. Objectives: To investigate the role of the levels of IMA in CAP and to evaluate its relationship with pneumonia severity.
Methods: A total of 150 patients with a diagnosis of CAP and 150 healthy individuals were included in the study. IMA levels were evaluated in both groups. The patients with CAP were divided into ambulatory, ward and intensive care groups, and their IMA levels were compared.
Results: There was no significant difference between the two groups in terms of age or gender (p>0.05 for both). No significant difference was observed in the IMA levels of the patient and control groups (p>0.05). The lowest IMA level was observed in the ambulatory group (p=0.001). When the patients in the ambulatory and hospitalized (ward and intensive care together) groups were evaluated, the cut-off value of IMA was 77.60 ABSU, sensitivity was 64.9%, specificity was 75.0%, positive predictive value was 89.2%, and negative predictive value was 40.3%.
Conclusion: In the management of patients with CAP, IMA seems to be a useful marker for CAP severity and hospitalization decision.

Keywords : Oxidative stress, biomarker, hospitalization decision, inflammation, risk stratification

Download Article


1. Ozlü T, Bülbül Y, Ozsu S. Community-acquired pneumonia based on the Turkish national data. Tuberk Toraks. 2007;55:191-212.
2. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection. 2004;32(4):234-238. doi:10. 1007/s15010-004-3107-z
3. Türkiye İstatistik Kurumu (Turkish Statistical Institute). Available at: http://www.tuik.gov.tr. Accessed March 2026.
4. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15(4):757-763. doi:10.1034/j.1399-3003.2000.15d21.x
5. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017:8416763. doi:10.1155/2017/8416763
6. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997;156(2 Pt 1):341-357. doi:10.1164/ajrccm.156.2.9611013
7. Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax. 1998;53(10):867-870. doi:10.1136/thx. 53.10.867
8. Cemek M, Caksen H, Bayiroğlu F, Cemek F, Dede S. Oxidative stress and enzymic-non-enzymic antioxidant responses in children with acute pneumonia. Cell Biochem Funct. 2006;24(3):269-273. doi:10.1002/cbf.1220
9. Wudkowska A, Goch J, Goch A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol Pol. 2010;68(4):431-437.
10. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-Preliminary report. Dis Markers. 2008; 24(6):311-317. doi:10.1155/2008/784313
11. Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009;24(4):333-341. doi: 10.2133/dmpk.24.333
12. Aran T, Unsal MA, Guven S, Kart C, Cetin EC, Alver A. Carbon dioxide pneumoperitoneum induces systemic oxidative stress: a clinical study. Eur J Obstet Gynecol Reprod Biol. 2012;161(1):80-83. doi:10.1016/j.ejogrb.2011.11.027
13. Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo). 2011;66(10):1677-1680. doi:10.1590/s1807-59322011001000003
14. Mastella AK, Moresco RN, da Silva DB, et al. Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. Biomed Pharmacother. 2009;63(10):762-766. doi:10.1016/j.biopha.2008.12.002
15. Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg. 2009;15(2):137.
16. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes-review and clinical implications. Clin Chem Lab Med. 2011; 49(2):177-184. doi:10.1515/CCLM.2011.037
17. Bar -Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19(4):311-315. doi:10.1016/s0736-4679(00)00255-9
18. Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37(2):384-392. doi:10. 1183/09031936.00035610
19. Bolatkale M, Duger M, Ülfer G, et al. A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin. Am J Emerg Med. 2017;35(8):1121-1125. doi:10.1016/j.ajem.2017.03.018
20. Delclaux C, Azoulay E. Inflammatory response to infectious pulmonary injury. Eur Respir J Suppl. 2003;42:10s-14s. doi:10.1183/09031936.03.00420203
21. Haran JP, Beaudoin FL, Suner S, Lu S. C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. Am J Emerg Med. 2013;31(1):137-144. doi:10.1016/j.ajem.2012.06.026
22. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349-355. doi:10.1183/09031936.00054507
23. Engel MF, Paling FP, Hoepelman AI, van der Meer V, Oosterheert JJ. Evaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review. Fam Pract. 2012; 29(4):383-393. doi:10.1093/fampra/cmr119
24. Durmus-Kocak N, Solakoglu-Ucar M. Yatan hastalarda Pnömoni Ağırlık Indeksi kullanılarak pnömoni tipi ve şiddetinin takip parametrelerine etkisinin karşılaştırılması. Klimik Derg. 2013;26:58-63. doi:10.5152/kd.2013.19
Article available in :
Volume 4, Issue 2, 2026
Page : 7-12
https://doi.org/10.51271/JOPIC-0077
Article Information
Received : 24 Şub 2026
Accepted : 29 Mar 2026
Published : 21 May 2026
Corresponding Author :

Melis Yağdıran: Department of Immunology and Allergy, Ankara Atatürk Sanatorium Training and Research Hospital, University of Health Sciences, Ankara, Turkiye

[email protected]
Citation : Yağdıran M, Parlak EŞ, Hasanoğlu HC, Erel Ö. Ischemia-modified albumin as a marker of disease severity and hospitalization in community-acquired pneumonia: a prospective case-control study. J Pulmonol Intens Care. 2026;4(2):37-42. doi:10.51271/JOPIC-0077

Read: 67
Download : 73
Cited: 0
_Footer